These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1615217)

  • 1. On the management of metastatic prostate cancer with LH-RH analogs.
    Blom JH; Schröder FH
    Recent Results Cancer Res; 1992; 124():33-41. PubMed ID: 1615217
    [No Abstract]   [Full Text] [Related]  

  • 2. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer.
    Schally AV; Comaru-Schally AM; Gonzalez-Barcena D
    Biomed Pharmacother; 1992; 46(10):465-71. PubMed ID: 1363977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of prostatic cancer by LH-RH agonist.
    Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetsu I
    Prog Clin Biol Res; 1987; 243A():429-34. PubMed ID: 3116552
    [No Abstract]   [Full Text] [Related]  

  • 5. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription practice for LH-RH analogs and androgen receptor antagonists in the treatment of advanced prostate cancer in Germany (1993-2003).
    Rohde V; Diemer T; Hauck E; Bestmann B; Miller J; Schröder H; Weidner W; Katalinic A
    Urol Int; 2006; 77(4):311-6. PubMed ID: 17135780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin-releasing hormone analogues for prostate cancer: untoward side effects of high-dose regimens acquire a therapeutical dimension.
    Jacobi GH; Wenderoth UK
    Eur Urol; 1982; 8(3):129-34. PubMed ID: 6281023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of LH_RH analogs in the treatment of cancer of the prostate. A report of the conference organized by ICI_Pharma Laboratories (part 1)].
    Prog Urol; 1991 Feb; 1(1):165-8. PubMed ID: 1364642
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of advanced cancer of the prostate.
    Orovan WL
    Can J Surg; 1989 Sep; 32(5):315-6. PubMed ID: 2670160
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules.
    Redding TW; Schally AV; Tice TR; Meyers WE
    Proc Natl Acad Sci U S A; 1984 Sep; 81(18):5845-8. PubMed ID: 6237365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New hormonal treatments of metastatic prostatic cancer. Review of the literature].
    Dubost JJ; Sauvezie B; Ristori JM; Thevenet JP; Rampon S
    Rev Rhum Mal Osteoartic; 1985 Oct; 52(10):577-85. PubMed ID: 3909364
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals.
    Pinski J; Schally AV; Yano T; Szepeshazi K; Halmos G; Groot K; Comaru-Schally AM; Radulovic S; Nagy A
    Prostate; 1993; 23(2):165-78. PubMed ID: 8378189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of neoadjuvant therapy in localized prostate cancer.
    Witjes WP; Oosterhof GO; Schaafsma HE; Debruyne FM
    Prostate; 1995 Dec; 27(6):297-303. PubMed ID: 7501541
    [No Abstract]   [Full Text] [Related]  

  • 15. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
    Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New aspects of anti-androgenic therapy of prostatic cancer].
    Portnoĭ AS
    Urol Nefrol (Mosk); 1985; (3):69-73. PubMed ID: 3892832
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of prostatic cancer with a depot form of a luteinizing hormone-releasing hormone analogue.
    Giuliani L; Barreca T; Giberti C; Franceschini R; Martorana G; Brancadoro MT; Salvemini M; Rolandi E
    Eur Urol; 1986; 12(6):390-4. PubMed ID: 2949979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concept for improving treatment of prostate cancer based on combination of LH-RH agonists with other agents.
    Schally AV; Redding TW; Paz-Bouza JI; Comaru-Schally AM; Mathe G
    Prog Clin Biol Res; 1987; 243A():173-97. PubMed ID: 2889215
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of carcinoma of the prostate with analogs of LHRH].
    Rubio Herrera MA; Calle Fernández JR
    Rev Clin Esp; 1986 Nov; 179(8):407-11. PubMed ID: 2951782
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.